Results from the IMmotion 150 clinical trial comparing atezolizumab with sunitinib

In this interview, Dr Daniel George from the Duke Cancer Institute, Durham, USA discusses results from the IMmotion 150 clinical trial. IMmotion 150 was a randomised phase II study comparing sunitinib with atezolizumab, a PD-L1 inhibitor, versus the combination of atezolizumab with bevacizumab, a VEGF-targeted antibody, as a first-line treatment for previously untreated renal cell carcinoma patients.

The study showed an improvement in progression-free survival for the atezolizumab plus bevacizumab arm compared to sunitinib, particularly in patients that had PD-L1–positive tumours. Patients with intermediate to high risk disease benefited the most from the combination of atezolizumab plus bevacizumab, with median progression-free survival of 12 months versus only about 5 or 6 months with sunitinib, suggesting that this is the group of patients that need to be targeted with this strategy.

Watch the video interview on OncLive here

Share this Post!

Related post